Lantern Pharma Future Growth
Future criteria checks 0/6
Lantern Pharma's earnings are forecast to decline at 3.8% per annum. EPS is expected to grow by 15.7% per annum.
Key information
-3.8%
Earnings growth rate
15.7%
EPS growth rate
| Biotechs earnings growth | 26.7% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 12 Nov 2024 |
Recent future growth updates
Recent updates
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?
Nov 05
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jun 12We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Dec 19We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Sep 02Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer
Jul 14Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth
May 20Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Feb 02We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Oct 13Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer
Aug 24Lantern Pharma: Drug Recycling With AI
Jun 08We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
May 05Lantern Pharma reports Q1 results
May 03Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like
Feb 19
Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma
Jan 04Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?
Dec 28Lantern: Early Stage 'Smart Drug' Discovery Company
Nov 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -19 | N/A | N/A | 1 |
| 12/31/2025 | N/A | -25 | N/A | N/A | 2 |
| 12/31/2024 | N/A | -21 | N/A | N/A | 2 |
| 9/30/2024 | N/A | -19 | -17 | -17 | N/A |
| 6/30/2024 | N/A | -18 | -15 | -15 | N/A |
| 3/31/2024 | N/A | -18 | -14 | -14 | N/A |
| 12/31/2023 | N/A | -16 | -14 | -14 | N/A |
| 9/30/2023 | N/A | -15 | -14 | -14 | N/A |
| 6/30/2023 | N/A | -14 | -14 | -14 | N/A |
| 3/31/2023 | N/A | -14 | -13 | -13 | N/A |
| 12/31/2022 | N/A | -14 | -13 | -13 | N/A |
| 9/30/2022 | N/A | -14 | -12 | -12 | N/A |
| 6/30/2022 | N/A | -16 | -13 | -13 | N/A |
| 3/31/2022 | N/A | -14 | -12 | -12 | N/A |
| 12/31/2021 | N/A | -12 | -11 | -11 | N/A |
| 9/30/2021 | N/A | -12 | -10 | -10 | N/A |
| 6/30/2021 | N/A | -9 | -8 | -8 | N/A |
| 3/31/2021 | N/A | -8 | -7 | -7 | N/A |
| 12/31/2020 | N/A | -6 | -6 | -6 | N/A |
| 9/30/2020 | N/A | -4 | -5 | -5 | N/A |
| 6/30/2020 | N/A | -3 | -2 | -2 | N/A |
| 3/31/2020 | N/A | -2 | -2 | -2 | N/A |
| 12/31/2019 | N/A | -2 | -2 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LTRN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LTRN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LTRN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if LTRN's revenue is forecast to grow faster than the US market.
High Growth Revenue: LTRN is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LTRN's Return on Equity is forecast to be high in 3 years time